Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 327 shares of the biopharmaceutical company’s stock after buying an additional 19 shares during the period. Proficio Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $207,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares in the last quarter. American Assets Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $427,000. TD Private Client Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 15 shares in the last quarter. Quantbot Technologies LP lifted its stake in Regeneron Pharmaceuticals by 266.7% during the fourth quarter. Quantbot Technologies LP now owns 528 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 384 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $330,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on REGN. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. Citigroup dropped their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating on the stock in a report on Monday, June 2nd. Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 target price on the stock. in a report on Friday, May 30th. Finally, Wells Fargo & Company lowered Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $700.00 to $580.00 in a report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $837.61.

Regeneron Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ:REGN opened at $572.39 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The company has a market cap of $61.80 billion, a PE ratio of 14.57, a price-to-earnings-growth ratio of 2.11 and a beta of 0.33. The firm has a 50 day simple moving average of $543.59 and a 200 day simple moving average of $611.77.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter last year, the company earned $9.55 EPS. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.